GAP vs NBIX · P/E 9.9, rev $15.09B vs P/E 45, rev $2.36B
The Gap, Inc. (GAP) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
The Gap, Inc. (GAP) is a apparel retail company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported GAP revenue for 2025-02-01 was $15.09B. Net income was $844.0M. Revenue was up 1.3% from 2024-02-03 to 2025-02-01. GAP currently screens at market cap $7.73B and trailing P/E 9.9.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
GAP currently screens at market cap $7.73B and trailing P/E 9.9. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the GAP and NBIX stock pages for the full models.
Not investment advice.